ABL1 and gastrointestinal stromal tumor: Imatinib, a selective inhibitor of BCR-Abl and c-kit receptor tyrosine kinase, is a clear example of the success of targeted therapy for chronic myelogenous leukemia (CML) and gastrointestinal stromal tumors (GIST).